---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-097802"
form_type: "8-K"
ticker: "NNVC"
cik: "0001379006"
company_name: "NANOVIRICIDES, INC."
filed_at: "2023-09-01T23:59:59+00:00"
generated_at: "2026-06-11T00:25:29.998899+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NanoViricides issues $1.5M convertible note to TheraCour in lieu of milestone payment

## Summary
- Issued $1.5M convertible promissory note to TheraCour (related party) in lieu of $1.5M cash milestone payment under Licensing Agreement.
- Note bears 12% annual interest, matures January 19, 2025; convertible into Series A Convertible Preferred Stock.
- Dr. Anil Diwan (President/Chairman) owns ~90% of TheraCour; recused from board vote on agreement.
- Note replaces milestone payment obligation for Initiation of Phase 1 Clinical Trials or Equivalent milestone.
- Company retains customary representations and warranties; note is unregistered security.

## SEC filing metadata
- accession: 0001104659-23-097802
- form_type: 8-K
- ticker: NNVC
- cik: 0001379006
- company_name: NANOVIRICIDES, INC.
- filed_at: 2023-09-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1379006/000110465923097802/0001104659-23-097802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1379006/000110465923097802/tm2325384d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-097802
- JSON: https://secwatch.observer/filing/0001104659-23-097802.json
- Plain text: https://secwatch.observer/filing/0001104659-23-097802.txt

## Key facts
- Debt Financings
  NANOVIRICIDES, INC. incurred convertible notes of $1,500,000 with TheraCour Pharma, Inc. at twelve percent (12%) per annum maturing January 19, 2025.
  - Instrument: convertible notes
  - Principal: $1,500,000
  - Counterparty: TheraCour Pharma, Inc.
  - Rate: twelve percent (12%) per annum
  - Maturity: January 19, 2025
  - Event: incurrence
  source text: by TheraCour within 3 months from Regulatory Approval. Upon achieving this milestone, the Registrant was obligated to pay TheraCour a cash milestone payment in the amount of $1,500,000. In lieu of this cash payment, TheraCour agreed to accept a Convertible Promissory Note in the principal amount of $1,500,000 effective July 19, 2023 (the “Note”). The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1379006/000110465923097802/0001104659-23-097802-index.htm
- Material Agreements
  NANOVIRICIDES, INC. entered into Deferred Expense Exchange Agreement with TheraCour Pharma, Inc. valued at $1,500,000 Convertible Promissory Note; interest rate 12% per annum; due 2025-01-19 (effective 2023-07-19).
  - Action: entry
  - Counterparty: TheraCour Pharma, Inc.
  - Value: $1,500,000 Convertible Promissory Note; interest rate 12% per annum; due 2025-01-19
  - Effective: 2023-07-19
  source text: On August 29, 2023, NanoViricides, Inc. (the “Registrant”) entered into a Deferred Expense Exchange Agreement (the “Agreement”) with TheraCour Pharma, Inc., a Connecticut corporation (“TheraCour”) effective as of July 19, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1379006/000110465923097802/0001104659-23-097802-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.